Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes
- Tamoxifen/Reloxifene Study Can Be Completed With Fewer Participants. Wang, Linda // JNCI: Journal of the National Cancer Institute;12/3/2003, Vol. 95 Issue 23, p1743
Reports on the conclusion made by the National Surgical Adjuvant Breast and Bowel Project that the Study of Tamoxifen and Raloxifene (STAR) can be completed with 3,000 postmenopausal women volunteers than it originally estimated. Design of STAR to compare whether the drug raloxifene can prevent...
- STAR Trial Enrollment Ends Ahead of Schedule. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;9/1/2004, Vol. 96 Issue 17, p1275
Reports that the Study of Tamoxifen and Raloxifene, a clinical trial of breast cancer prevention in North America, has reached its enrollment goal in June 2004. Enrollment of postmenopausal women.
- Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? Prasad, Vinay; Diener-West, Marie // CMAJ: Canadian Medical Association Journal;6/16/2015, Vol. 187 Issue 9, pE276
The article comments on the renewed interest in the use of medication for the primary chemoprevention of breast cancer. Topics discussed include clinical trials which confirmed the role of raloxifene, tamoxifen and other selective estrogen-receptor modulators in reducing breast cancer risk, the...
- Breast cancer prevention trials `can re-start'. Gavaghan, Helen // Nature;6/16/1994, Vol. 369 Issue 6481, p515
Reports on the recommendation by the Food and Drug Administration oncology advisory committee that the clinical trial of the breast cancer drug tamoxifen should be allowed to continue despite claims that it increases women's chances of developing endometrial cancer. National Cancer Institute's...
- Raloxifene cuts risk of endometrial cancer. // Contemporary OB/GYN;Oct2008, Vol. 53 Issue 10, p22
The article discusses research being done on the use of raloxifene in reducing the development of endometrial cancer and its link with a more favorable histologic type in patients who do develop cancer. It references a study by Angela DeMichele et al., published in the September 1, 2008 issue of...
- Breast cancer advocates take aim at industry polluters. // HealthFacts;Nov95, Vol. 20 Issue 198, p3
Reports on Massachusetts-based Women's Community Cancer Project's drive against environmental pollution in an effort to prevent breast cancer. Launching of the National Cancer Industry Awareness Month in October 1995; Indifference towards the use of tamoxifen as an anti-cancer drug.
- Tamoxifen guidelines for breast cancer prevention premature, researcher says. // Formulary;Jun98, Vol. 33 Issue 6, p512
Reveals that the development of formal guidelines for the use of tamoxifen for breast cancer prevention is premature, according to Richard Clarfeld, clinical professor of surgery at the University of Washington. Results of long-term tamoxifen therapy in the Breast Cancer Prevention Trial; Use...
- Cancer preventer. Brownlee, Shannon // U.S. News & World Report;04/20/98, Vol. 124 Issue 15, p63
Reports on the announcement regarding tamoxifen, a drug which reduces the chance of women developing breast cancer. Reasons why studies on the drug were ended a year early; Side effects and dangers in taking the drug.
- Prevent breast cancer. Gregory, Deborah // Essence (Essence);Sep93, Vol. 24 Issue 5, p44
Discusses the Breast Cancer Prevention Trial aimed at examining the preventive capability of tamoxifen. Number of black women enrolled in breast-cancer studies; Tamoxifen's mechanism of action; Requirement for study participants; Contact information.